Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell Anemia
Year: 2011
Type: article
Abstract: Letters15 November 2011Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell AnemiaJames G. Taylor, MD, Deepika S. Darbari, MD, Irina Maric, MD, Zachariah McIver, MD, and Diane C. Arthur, MDJames G. Taylor, MDFrom National Institutes of Health, Bethesda, MD 20892-1476., Deepika S. Darbari, MDFrom National Institutes of Health, Bethesda, MD 20892-1476., Irina Maric, MDFrom National Institutes of Health, Bethesda, MD 20892-1476., Zachariah McIver, MDFrom National Institutes of Health, Bethesda, MD 20892-1476., and Diane C. Arthur, MDFrom National Institutes of Health, Bethesda, MD 20892-1476.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-10-201111150-00024 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This article has been corrected. The original version (PDF) is appended to this article as a supplement.Background: Hydroxyurea is an antimetabolite that minimizes pain and prolongs survival in patients with sickle cell anemia (1). It is not widely prescribed because of concerns about late effects, including cancer (2), and its leukemogenic risk is extrapolated from its reported risk in myeloproliferative disorders (3). Few cases of leukemia in patients with sickle cell anemia have been described, and only half of them report cytogenetics (4). Acute myelogenous leukemia (AML) in patients with sickle cell anemia receiving hydroxyurea treatment is exceptionally rare, ...References1. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85:403-8. [PMID: 20513116] MedlineGoogle Scholar2. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939-55. [PMID: 18458272] LinkGoogle Scholar3. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417-21. [PMID: 16810617] CrossrefMedlineGoogle Scholar4. Ferster A, Sariban E, Meuleman N; Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea. Malignancies in sickle cell disease patients treated with hydroxyurea [Letter]. Br J Haematol. 2003;123:368-9. [PMID: 14531924] CrossrefMedlineGoogle Scholar5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51. [PMID: 19357394] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: James G. Taylor, MD; Deepika S. Darbari, MD; Irina Maric, MD; Zachariah McIver, MD; Diane C. Arthur, MDAffiliations: From National Institutes of Health, Bethesda, MD 20892-1476.Disclosures:Patent pending: 12/423,750 (U.S. Application); Stock/stock options: Amgen, AstraZeneca, Bristol-Myers Squibb, Fidelity Select Biotech, General Electric, Monsanto, ATT, Chevron Corporation, Citigroup, Comcast, Entergy, Exxon Corporation, Fidelity Select Energy, Hewlett Packard, Intel, IBM, Juniper Networks, Marine Products Corp., Motorola, Proctor and Gamble, Rollins, RPC, Sysco, Tokeville Gold Fund, Traveller Companies. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease Sophie Lanzkron , John J. Strouse , Renee Wilson , Mary Catherine Beach , Carlton Haywood , HaeSong Park , Catherine Witkop , Eric B. Bass , and Jodi B. Segal Correction: Therapy-Related Acute Myelogenous LeukemiaCorrection: Therapy-Related Acute Myelogenous Leukemia Metrics Cited byPure Erythroid Leukemia in a Sickle Cell Patient Treated with HydroxyureaMyeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literatureOccurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patientEffect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trialOvarian Sertoli-Leydig tumor after bone marrow transplant for sickle cell diseasePharmacovigilance for Veterinary Medicinal ProductsAccelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell diseaseUpdate on the use of hydroxyurea therapy in sickle cell diseaseHydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefitAntineoplastic DrugsCorrection: Therapy-Related Acute Myelogenous LeukemiaCorrection: Therapy-Related Acute Myelogenous Leukemia 15 November 2011Volume 155, Issue 10Page: 722-724KeywordsAcute myeloid leukemiaAnemiaBone marrowChromosomesCytogeneticsHemoglobinKaryotypesMean corpuscular volumeMyeloproliferative disordersNeutropenia ePublished: 15 November 2011 Issue Published: 15 November 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Source: Annals of Internal Medicine
Institution: National Institutes of Health
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2023030086